These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 34045175)

  • 1. Bone-modifying Agents (BMAs) in Breast Cancer.
    Shapiro CL
    Clin Breast Cancer; 2021 Oct; 21(5):e618-e630. PubMed ID: 34045175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
    Shapiro CL; Moriarty JP; Dusetzina S; Himelstein AL; Foster JC; Grubbs SS; Novotny PJ; Borah BJ
    J Clin Oncol; 2017 Dec; 35(35):3949-3955. PubMed ID: 29023215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: A meta-analysis of 13 randomized controlled trials.
    Mei M; Xiang Z; Yang J; Xiang R
    Curr Probl Cancer; 2020 Apr; 44(2):100507. PubMed ID: 31732237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
    von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
    Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
    Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
    Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoporosis management in patients with breast cancer: EMAS position statement.
    Trémollieres FA; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; van der Schouw YT; Senturk LM; Simoncini T; Stevenson JC; Stute P; Rees M
    Maturitas; 2017 Jan; 95():65-71. PubMed ID: 27802892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of bone loss due to endocrine therapy during cancer treatment.
    Khan MI
    Osteoporos Int; 2023 Apr; 34(4):671-680. PubMed ID: 36656338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
    Van Poznak C; Somerfield MR; Barlow WE; Biermann JS; Bosserman LD; Clemons MJ; Dhesy-Thind SK; Dillmon MS; Eisen A; Frank ES; Jagsi R; Jimenez R; Theriault RL; Vandenberg TA; Yee GC; Moy B
    J Clin Oncol; 2017 Dec; 35(35):3978-3986. PubMed ID: 29035643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
    Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.
    Hershman DL; McMahon DJ; Crew KD; Cremers S; Irani D; Cucchiara G; Brafman L; Shane E
    J Clin Oncol; 2008 Oct; 26(29):4739-45. PubMed ID: 18711172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.
    Mitchell AP; Nemirovsky D; Mishra Meza A; Chakraborty N; Persaud S; Farooki A; Morris MJ
    JCO Oncol Pract; 2024 Mar; 20(3):393-400. PubMed ID: 38190588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
    Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
    J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Denosumab in the Prevention of Skeletal-Related Events Among Patients With Breast Cancer With Bone Metastasis in India.
    Wadhwa R; Gupta N; Dixit J; Malhotra P; Lakshmi P; Prinja S
    JCO Glob Oncol; 2024 Mar; 10():e2300396. PubMed ID: 38452304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.
    Chen C; Li R; Yang T; Ma L; Zhou S; Li M; Zhou Y; Cui Y
    Clin Ther; 2020 Aug; 42(8):1494-1507.e1. PubMed ID: 32718784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database.
    Hatoum HT; Lin SJ; Smith MR; Barghout V; Lipton A
    Cancer; 2008 Sep; 113(6):1438-45. PubMed ID: 18720527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.